Recursion Pharmaceuticals vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.
About
Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Recursion Pharmaceuticals vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.